Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$1.24
-2.4%
$1.27
$1.01
$11.55
$3.06M0.53775,205 shs467,769 shs
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
$0.71
-7.2%
$1.21
$0.64
$3.00
$1.92M0.37185,862 shs23,089 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$2.87
$3.24
$1.75
$9.37
$4.71M1.38806,313 shs12,879 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$0.31
+0.7%
$0.31
$0.20
$1.79
$3.46M0.724.16 million shs218,301 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
0.00%-2.36%+5.97%-10.79%-86.80%
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
0.00%-8.38%-39.44%-40.94%-69.85%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00%-5.59%-16.57%+31.05%+1,252.50%
SciSparc Ltd. stock logo
SPRC
SciSparc
0.00%+4.05%-2.93%+6.13%-61.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
2.9935 of 5 stars
3.54.00.00.02.70.01.3
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
1.1401 of 5 stars
0.05.00.00.03.30.80.0
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.8909 of 5 stars
0.05.00.00.03.30.00.0
SciSparc Ltd. stock logo
SPRC
SciSparc
0.8339 of 5 stars
0.05.00.00.01.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
3.00
Buy$10.00706.45% Upside
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/A$2.35 per shareN/A
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/AN/AN/AN/A($1.19) per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.33N/AN/A$2.73 per share1.05
SciSparc Ltd. stock logo
SPRC
SciSparc
$1.31M2.64N/AN/A$0.86 per share0.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-$9.57M-$38.38N/AN/AN/AN/A-250.28%-195.57%8/11/2025 (Estimated)
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
-$3.59M-$1.45N/AN/AN/AN/A-189.35%8/6/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$3.10N/AN/AN/A-24.23%-58.73%-21.05%8/6/2025 (Estimated)
SciSparc Ltd. stock logo
SPRC
SciSparc
-$6.28MN/A0.00N/AN/AN/AN/AN/A

Latest ENVB, SNOA, LIXT, and SPRC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
5/14/2025Q1 2025
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-$3.45-$1.22+$2.23-$1.22N/AN/A
5/12/2025Q1 2025
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/A-$0.29N/A-$0.29N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/AN/A
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/A
4.08
4.08
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/A
4.26
4.26
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.09
2.38
SciSparc Ltd. stock logo
SPRC
SciSparc
N/A
5.36
5.28

Institutional Ownership

CompanyInstitutional Ownership
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
13.82%
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
5.10%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
SciSparc Ltd. stock logo
SPRC
SciSparc
25.06%

Insider Ownership

CompanyInsider Ownership
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
3.20%
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
14.80%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.90%
SciSparc Ltd. stock logo
SPRC
SciSparc
1.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
202.47 million2.39 millionNot Optionable
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
42.68 million2.29 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.58 millionNot Optionable
SciSparc Ltd. stock logo
SPRC
SciSparc
411.23 million11.06 millionNot Optionable

Recent News About These Companies

SciSparc Announces 1-for-21 Reverse Share Split
SciSparc announces collaboration with Clearmind Medicine
SciSparc files to sell 61.21M ordinary shares for holders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enveric Biosciences stock logo

Enveric Biosciences NASDAQ:ENVB

$1.24 -0.03 (-2.36%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$1.26 +0.02 (+2.02%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Lixte Biotechnology stock logo

Lixte Biotechnology NASDAQ:LIXT

$0.71 -0.06 (-7.19%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$2.50 +1.79 (+249.85%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$2.87 0.00 (0.00%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$5.00 +2.13 (+74.22%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

SciSparc stock logo

SciSparc NASDAQ:SPRC

$0.31 +0.00 (+0.72%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$0.30 -0.01 (-2.60%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.